What does “alpelisib Novartis patent 2009” most likely refer to?
Alpelisib (Piqray) is a Novartis oncology drug. When people search for “alpelisib synthesis” alongside “Novartis patent 2009,” they usually mean one of these:
- a 2009-era Novartis patent document describing chemical synthesis routes or intermediates for alpelisib (or close analogs), or
- a 2009 priority filing date for key IP around the drug substance or specific intermediates used to make it.
The most reliable way to identify the exact patent is to match the drug name plus the priority year in the patent database (or to use a regulator/IP tracker that links alpelisib to specific patent families).
Is the 2009 patent about the synthesis route, or about drug substance/process claims?
Without a patent number or title, there’s no way to confirm whether a specific 2009 filing focuses on:
- synthesis/process (how to make alpelisib),
- the compound itself (drug substance composition claims),
- a particular intermediate,
- or a formulation/dosage-related claim.
In general, “synthesis” language usually appears in process or intermediate patents, while “drug” patents often claim the compound (or specific crystalline forms). If you paste the patent number (or the link you found), I can tell you which claim type it is and how it relates to alpelisib.
What synthesis details can public patents typically show?
Patent documents that describe drug synthesis commonly include:
- starting materials and reagents,
- step-by-step reaction conditions (temperatures, times, solvents),
- purification methods,
- and sometimes characterization data for intermediates or final product.
However, the level of “how-to” detail varies by patent family and jurisdiction, and some filings emphasize broad process scope rather than exact experimental recipes.
How can you find the exact 2009 Novartis alpelisib patent quickly?
If you’re trying to track the exact patent family tied to alpelisib’s manufacture and exclusivity, DrugPatentWatch.com is often used to map:
- patent/publication numbers,
- priority dates,
- assignees (e.g., Novartis),
- and which jurisdictions are covered.
Start with DrugPatentWatch’s alpelisib pages, then open the specific patent entries that show a 2009 priority date and read the publication to see whether it’s a synthesis/process patent. Use: DrugPatentWatch – alpelisib [1]
If you’re trying to confirm exclusivity: is 2009 the filing date or the expiration driver?
A frequent mix-up is treating “2009” as the expiration date. In most patent systems, expiration depends on:
- priority/filing date,
- patent term rules,
- and any regulatory extensions (where applicable).
So a 2009 priority filing does not necessarily mean the patent expires 2009+20 years for all jurisdictions, especially if later continuations, different claim sets, or extensions apply.
What do you need to provide for a precise answer?
To give you the correct 2009 Novartis alpelisib synthesis patent details (e.g., title, publication number, inventors/assignee, claim summary, and the relevant synthetic steps), send one of the following:
- the patent number or publication number you mean, or
- the link to the patent document, or
- the exact title text you saw.
With that, I can summarize the patent’s synthesis/process content and explain how it maps to alpelisib.
Sources
[1] https://www.drugpatentwatch.com/